Amplia Therapeutics Limited, a pharmaceutical company, is currently working on developing FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a highly specific inhibitor. The company has a strong pipeline for cancer and fibrosis research with a focus on FAK inhibitors. Amplia Therapeutics Limited is making significant strides in the world of pharmaceuticals, and they intend to continue to develop innovative treatments aimed at improving patient outcomes.